

## Asthma Indicators for LHIN 8: Central

Indicator	Asthma Indicators for LHIN 8: Central																									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020*	2021*
1. PFT used for diagnosis (% of incident asthma) <sup>†</sup>	52.96	54.65	51.43	48.77	46.86	44.21	43.24	41.25	43.06	44.62	45.90	46.49	45.83	46.37	46.63	47.06	47.22	48.36	50.88	52.01	52.77	51.32	51.72	53.77	50.48	56.99
2. PFT used for monitoring (% of prevalent asthma) <sup>†</sup>	17.34	15.58	15.19	13.35	12.02	11.10	9.54	8.75	8.15	8.09	8.11	7.86	7.26	7.47	7.42	7.11	6.84	6.41	6.28	6.50	6.61	6.65	6.60	6.46	6.09	2.94
3. ≥1 ICS prescription (% of prevalent asthma) <sup>‡</sup>	55.46	53.83	52.34	50.60	50.43	49.88	48.14	46.17	46.15	46.21	44.86	45.61	45.04	44.84	45.00	47.41	46.97	47.29	46.65	47.04	46.13	43.26	40.56	39.37	39.93	31.41
4. ≥1 β2-agonist prescription (% of prevalent asthma) <sup>‡</sup>	56.42	53.64	51.54	49.56	48.96	46.64	43.37	40.19	38.90	38.85	36.37	35.68	33.56	32.22	32.19	32.59	30.98	30.90	28.01	20.74	20.78	19.63	20.29	17.49	13.66	11.99
5. ≥1 asthma ED visit (% of prevalent asthma)	4.11	3.55	3.22	2.94	2.81	2.48	2.35	1.53	1.40	1.45	1.40	1.22	1.07	0.99	0.96	0.89	0.81	0.82	0.77	0.82	0.74	0.73	0.74	0.66	0.62	0.24
6. ≥1 asthma physician office visit (% of prevalent asthma)	37.71	34.11	31.48	30.05	27.86	27.27	24.35	22.53	21.62	21.19	20.75	20.13	18.53	17.98	18.05	16.53	15.45	15.21	14.69	14.89	14.59	14.16	14.31	13.25	13.49	7.53
7. β2-agonist use (% of prevalent asthma) <sup>‡</sup>																										
0 canisters per year	43.58	46.36	48.46	50.44	51.04	53.36	56.63	59.81	61.10	61.15	63.63	64.32	66.44	67.78	67.81	67.41	69.02	69.10	71.99	79.26	79.22	80.37	79.71	82.51	86.34	88.01
1-2 canisters per year	20.30	20.10	19.93	19.52	20.07	19.48	18.16	17.29	17.56	18.34	16.92	16.83	16.39	15.73	16.27	16.33	15.99	16.45	15.14	10.92	11.14	10.34	10.96	9.49	7.56	5.81
≥3 canisters per year	36.12	33.54	31.61	30.04	28.89	27.16	25.21	22.90	21.35	20.51	19.45	18.85	17.17	16.49	15.92	16.26	14.99	14.45	12.88	9.82	9.64	9.30	9.33	8.00	6.09	6.18

\*Reporting period is from April 1996 to March 2022. Data for 2020 and 2021 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department; ODB = Ontario Drug Benefit; OHIP = Ontario Health Insurance Plan; LHIN = Local Health Integration Network; HSU = health services use

<sup>†</sup>PFT data refers to individuals aged 7-99 years in the asthma prevalent population. OHIP billings for PFT may have undercounted its utilization as it can be part of “bundled care” performed by the provider and therefore not billed to OHIP separately.

<sup>‡</sup>Drug use data refers to individuals aged 66-99 years with complete year ODB coverage in the asthma prevalent population.

### Technical notes:

<sup>a</sup>OHIP data was up to February 2022 when the tables were created.

<sup>b</sup>For asthma incidence from September 2019 to March 2021, PFT data for 2.5-year post asthma incidence are not complete as latest data were available up to February 2022 at the time when the tables were created.

<sup>c</sup>Individuals with missing LHIN, rurality, or without OHIP coverage were excluded.

<sup>d</sup>Asthma incidence of the year were excluded from this table, except for indicator 1.

<sup>e</sup>Index date is defined as the first service date of asthma HSU, or any HSU if there was no asthma HSU, or April 1 if there was no HSU during the year.

### Asthma indicators - detailed description:

1. Percent of asthma incidence aged 7 years and above with a PFT in one year prior to or 2.5 years after incidence date<sup>a,c</sup>
2. Percent of asthma prevalence aged 7 years and above with a PFT in one year prior to the index date<sup>a,c,e</sup>
3. Percent of asthma prevalence 66 years and above with at least one prescription of ICS in one year prior to the index date<sup>c,e</sup>
4. Percent of asthma prevalence aged 66 years and above with at least one prescription of β2-agonist in one year prior to the index date<sup>c,e</sup>
5. Percent of asthma prevalence with at least one ED visit in one year prior to the index date<sup>c,e</sup>
6. Percent of asthma prevalence with at least one physician office visit (in-person and virtual) in one year prior to the index date<sup>c,e</sup>
7. Distribution of the three categories of β2-agonist use for asthma prevalence aged 66 years and above in one year prior to the index date<sup>c,d</sup>

**Source:** This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.